CUPERTINO, Calif., April 3, 2017 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive
Officer, will be presenting at the H.C. Wainwright NASH Investor
Conference on Monday, April 3
at 4:40 p.m. Eastern
Time. The conference is being held at the St. Regis
Hotel in New York City.
A live audio webcast of the presentation will be available by
accessing http://wsw.com/webcast/hcw/drrx.
A live audio webcast of the presentation will also be available
by accessing DURECT's homepage at www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing new
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 1 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury, chronic metabolic disorders such as
nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH) and other disorders of the liver both broad
and orphan, and inflammatory conditions such as psoriasis.
DURECT's advanced oral, injectable, and transdermal delivery
technologies are designed to enable new indications and enhanced
attributes for small-molecule and biologic drugs. One
late-stage product candidate in this category is
POSIMIR® (SABER®-Bupivacaine), an
investigational analgesic product intended to address key unmet
needs in postoperative pain management. Another late stage
product candidate is REMOXY® ER (oxycodone), an
investigational extended release pain relief drug based on DURECT's
ORADUR® technology. For more information, please
visit www.durect.com.
NOTE: POSIMIR®, SABER® and
ORADUR® are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners.
POSIMIR, REMOXY ER and DUR-928 are investigational drugs under
development and have not been approved for sale by the U.S. Food
and Drug Administration or other health authorities.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/durect-to-present-at-the-hc-wainwright-nash-investor-conference-300432802.html
SOURCE DURECT Corporation